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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S176Conclusions: This open-label study shows that i.a. HA injection for TMCJ
OA leads to a signiﬁcant improvement in all the investigated parameters,
which is still present after six months from baseline. There are currently
two broad categories proposed for the mechanism of action by which HA
may elicit short-and long-term pain relief: rheological or biomechanical
and biological (anti-inﬂammatory, anabolic, analgesic, chondroprotective
and anticatabolic) effects through interactions between HA and its
receptors CD44, RHAMM, ICAM-1. It is possible that one of the functions of
CD44 in stem cells may be to facilitate the endocytosis of HA which then
may act as a protector of their DNA from oxidants. Our study conﬁrms that
i.a. injections of HA in TMCJ are easily administered, and may give symp-
tomatic beneﬁt with minimal side effects.
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CHRONIC EFFECTS OF A FLEXIBLE AND MINIMALIST FOOTWEAR ON
CLINICAL, FUNCTIONAL AND GAIT BIOMECHANICAL ASPECTS IN THE
KNEE OSTEOARTHRITIS: A SINGLE-BLIND RANDOMIZED CLINICAL
TRIAL
F. Trombini-Souza, A. Matias, M. Yokota, C. Schainberg, R. Fuller,
I.C. Sacco. Univ. of Sao Paulo, Sao Paulo, Brazil
Purpose: Recent studies have shown that the acute use of shoes that
mimic barefoot gait decrease substantially knee loads while walking in
elderly with knee osteoarthritis (OA). Probably due to methodological
difﬁculties to implement this type of conservative treatment during
extended period, the effectiveness of minimalist footwear has not been
evaluated yet in elderly patients with knee OA. The purpose is to describe
a randomized clinical trial protocol for evaluating the therapeutic effect of
a minimalist (ﬂexible, non-heeled) and inexpensive footwear on clinical,
functional, and biomechanical gait in elderly women with knee OA.
Methods: Fifty six elderly womenwith knee OA grade 2 or 3 (Kellgren and
Lawrence) will be randomized in blocks and allocated in the intervention
group thatwill use aﬂexiblenon-heeled shoes -Moleca for at least 6hours
daily or in the control group, which could not use these shoes or be under
physical therapy or acupuncture treatment throughout these sis months.
The use of Paracetamol 500mg every six hour was allowed for both groups
in case of pain.Moleca (CalçadosBeiraRio S.A., NovoHamburgo, RS, Brazil)
is a women's double canvas ﬂexible ﬂat walking shoe without heels, with
a 5-mm anti-slip rubber sole and a 3-mm internal wedge of ethylene vinyl
acetate. The mean weight is 17219.6 g, ranging from 142 to 193 g
depending on the size. Both groups will be followed during 6months. They
will be assessed at baseline condition, after 3 months (intervention group)
and after 6months of baseline condition (end of intervention, both groups).
All the assessments will be performed by a physiotherapist that is blind to
which group the patientwas allocated. Themain outcome assessment is the
pain WOMAC score and the secondary outcomes are other WOMAC scores
pain assessment (visual analogue scale - VAS), Lequesne index, Six-Minute
Walk Test, and biomechanical gait analysis by means of 6 infrared cameras
and a multi-component force plate to determine the knee adduction
moment during gait. At baseline, all patients receive a diary to record the
hours of daily use of footwear intervention. Every two weeks, the same
physiotherapist carries phone calls to all patients in order to verify adher-
ence to treatment and the correctﬁlling this diary. The intergroupand inter-
moments will be performed by repeated measures analysis of variance
(a¼0.05). This Trial was approved by the local Ethics Committee and was
registered in ClinicalTrials.gov Identiﬁer: NCT01342458.
Results: Six hundred thirty-four elderly women have been contacted so far
and 20 have already been allocated in the intervention group (9) and in the
control (11). Five patients from intervention group have already completed
all 3 assessments and ﬁnished the protocol. The preliminary results have
shown that the elderly women of the intervention group have used the
Moleca shoe for an average monthly of 7 hours and 24 minutes ( 3:47),
corresponding to approximately 50% of the home-work hours of the day.
Conclusion: This is the ﬁrst randomized clinical trial protocol to assess the
chronic effect of a minimalist footwear on the clinical, functional and gait
biomechanics of elderly women with knee osteoarthritis. We expect that
the use of Moleca shoes for 6 months provides pain relief, reduction of
the knee adduction moment while walking and improves joint function in
elderly women with knee OA, and therefore can be considered as another
inexpensive option for conservative OA treatment.The authors are pleased to acknowledge the ﬁnancial support of State of
São Paulo Research Foundation - FAPESP (processes: 2011/01640-8, 2011/
03300-0, 2011/03069-6).
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RANDOMIZED, DOUBLE-BLIND CONTROL TRIAL OF PERI-ARTICULAR
HYALURONIC ACID:BOTULINUS TOXIN INJECTION IN LATERAL
EPICONDYLOSIS.
R.J. Petrella 1,2, J. Decaria 1, M. Petrella 1. 1U Western Ontario, London, ON,
Canada; 2 Lawson Hlth.Res. Inst., London, ON, Canada
Purpose: To compare and describe the effects of peri-articular hyaluronic
acid (HA) coadminsitered with botulinus toxin (Botox) versus placebo in
lateral epicondylosis.
Methods: 28 patients with elbow pain longer than two weeks and less
than 12 months, particularly exacerbated during resisted dorsiﬂexion of
thewrist with the elbow in full extensionwith a VAS score> 4.5 cm on a 0-
10 cm VAS were included. Assessments were done at baseline, days 7, 14,
30 and 90. Efﬁcacymeasures included patient's visual analogue scale (VAS)
of pain at rest (0-100 mm) and following assessment of grip strength (0-
100 mm). Grip strength was determined using a jamar hydraulic hand
dynamometer. Other assessments included patients’ global assessment of
elbow injury (5 point categorical scale; 1 ¼ no disability, 5 ¼ maximal
disability), patients’ assessment of normal function/activity (5 point
categorical scale), patients/physician satisfaction assessment (10 point
categorical scale), and adverse events as per WHO deﬁnition. Differences
between groups were determined using an intent-to-treat ANOVA. After
outcome assessment, patients were randomized to treatment with a single
injection of: HA + Botox (0.7 cc HA + 40 units Botox), HA alone (0.7 cc),
Botox (40 units), placebo (normal saline 0.7 cc). Injections were done free-
hand into the origin of the extensor carpi radialis brevis (ECRB).
Results: All patients completed the trial. Adverse events included pain and
swelling in one patient in the HA group at day 7 and ECRB weakness for 48
hours in one patient in the Botox group following injection. At 7 days,
a signiﬁcant improvement (p<0.05) from baseline and versus placebo in
VAS pain at rest and following grip testing was observed in all three
treatment groups. Grip strength was greater (p<0.05) for HA+Botox vs
other groups at 14, 30 and 90 days. Further, HA +Botox showed small but
signiﬁcant patient perception of normal function versus HA or Botox at one
month (p<0.05). However, at 90 days, HA+ Botox showed signiﬁcantly
(p<0.03) greater physician satisfaction versus all other groups. There were
no differences in patient global satisfaction between treatment groups at 7
or 90 days, but HA + Botox showed greater satisfaction at 14 and 30 days.
Conclusion: Peri-articular HA + Botox produced superior clinical and
statistical improvement in short- and long-term pain and function
compared to placebo and Ha or Botox alone with serious adverse effects.Epidemiology & Health Services Research
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HORMONE REPLACEMENT THERAPY PREVENTS FAILURE AFTER TOTAL
KNEE (TKA) AND HIP (THA) ARTHROPLASTY: A POPULATION-BASED
RETROSPECTIVE COHORT STUDY.
D. Prieto-Alhambra 1,2, M. Javaid 1, A. Judge 1, J. Maskell 3, C. Cooper 1,3,
N.K. Arden 1. 1Botnar Res. Ctr., Univ. of Oxford, Oxford, United Kingdom;
2 Inst. Català de la Salut-IDIAP Jordi Gol, Barcelona, Spain; 3MRC Lifecourse
Epidemiology; Southampton Univ., Southampton, United Kingdom
Purpose: Rates of primary total knee (TKA) and hip (THA) arthroplasties
are increasing worldwide. Together with patient reported outcomes,
implant survival is an important element in the evaluation of joint
replacement surgery. There is an urgent need to identify potential inter-
ventions to improve implant outcomes. Hormone replacement therapy
(HRT) might minimise osteolysis and loosening through its anti-resorptive
effects, and hence improve prosthesis survival.
